Taysha Gene Therapies (TSHA) Retained Earnings (2019 - 2026)

Taysha Gene Therapies has disclosed Retained Earnings across 8 years of filings, most recently posting -$753.7 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$753.7 million, down 32870.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$753.7 million (down 32870.69% YoY), and the FY2025 annual result was -$711.3 million, down 18.1% from the prior year.
• Retained Earnings came in at -$753.7 million for Q1 2026 at Taysha Gene Therapies, down from -$711.3 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$251000.0 in Q1 2024 to a low of -$753.7 million in Q1 2026.
• The 5-year median for Retained Earnings is -$419.1 million (2023), against an average of -$382.5 million.
• Across the five-year window, Retained Earnings soared 99.94% in 2024 and plunged 32870.69% in 2026, its largest moves.
• Taysha Gene Therapies' Retained Earnings stood at -$401.4 million in 2022, then fell by 27.79% to -$513.0 million in 2023, then dropped by 17.41% to -$602.3 million in 2024, then retreated by 18.1% to -$711.3 million in 2025, then slipped by 5.96% to -$753.7 million in 2026.
• The last three Retained Earnings figures came in at -$753.7 million (Q1 2026), -$711.3 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.